Southwest Oncology Group studies in hormone-refractory prostate cancer

M. H A Hussain*, B. Blumenstein, M. Eisenberger, E. D. Crawford

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Virtually all patients with hormone-refractory prostate cancer will eventually succumb to their disease with no demonstrable increase in survival with ally second-line therapy, thus making the conventional approach to the treatment of this disease palliative. The Southwest Oncology Group (SWOG) Genitourinary Committee strategy in investigating therapy for hormone- refractory prostate cancer is focused on the application of biologically guided treatments targeting primary patients with limited prior hormonal therapy, taking into account evolving concepts regarding the definitions of 'hormone-refractory' disease and response criteria. This report reviews data from selected SWOG studies conducted in the past 10 years, and outlines the rationale and design of current and future studies conducted by the Genitourinary Committee of the SWOG in hormone-refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)24-27
Number of pages4
JournalSeminars in Oncology
Issue number6 SUPPL. 14
StatePublished - 1996

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Southwest Oncology Group studies in hormone-refractory prostate cancer'. Together they form a unique fingerprint.

Cite this